Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MARGIN-2 fluorescence-guided breast-conserving surgery study
NL-OMON53445Phase 2Terminated
- Sponsor
- University Medical Center Groningen
- Start
- Mar 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab-IRDye800CW in breast cancer, sponsored by University Medical Center Groningen. Primary endpoint: Tumor-positive margin detection rate. Started Mar 2024; status: terminated.
02
Drugs
bevacizumab-IRDye800CW
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON53445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53445.